Funding
Funding not disclosed
Founders
Product
Problem
Women's reproductive health conditions such as uterine fibroids, endometriosis, and preterm labor often lack effective, convenient treatment options, impacting fertility, pregnancy outcomes, and overall quality of life. Current therapies may involve invasive procedures or have significant side effects, creating a need for more accessible and tolerable alternatives.
Solution
ObsEva is developing a pipeline of orally-administered compounds designed to address unmet needs in women's reproductive health. These clinical-stage therapeutics target key pathways involved in uterine fibroids, endometriosis, assisted reproductive technology, and preterm labor. By focusing on oral administration, ObsEva aims to provide women with more convenient and less invasive treatment options. The company's research seeks to improve fertility outcomes, pregnancy management, and overall reproductive health for women worldwide.
Target Audience
The primary target audience includes women suffering from uterine fibroids, endometriosis, or at risk of preterm labor, as well as clinicians specializing in reproductive health and fertility.
Features
- Orally-administered compounds for improved patient convenience and compliance
- Targeted therapies addressing the underlying mechanisms of uterine fibroids, endometriosis, and preterm labor
- Clinical-stage pipeline with ongoing trials to evaluate safety and efficacy
- Focus on enhancing fertility treatments and pregnancy management